Junichi Ito

Identification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target

Kun-Yi Hsin, Hiroaki Kitano, Y-h. Taguchi, 2015, Scientific Reports.

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Y. Funahashi, J. Matsui, Yu Kato, 2018, Cancer science.

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant

Benoit H. Dessailly, K. Mizuguchi, C. Coban, 2013, PloS one.

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

H. Kitano, Samik Ghosh, Ayako Yachie-Kinoshita, 2019, PloS one.

Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome

K. Mizuguchi, K. Ishii, S. Akira, 2014, Nature Communications.

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

T. Owa, H. Kouji, Yuji Yamamoto, 2021, Cancer Research.